About Luna
Luna by Ablatus is a patented radiofrequency ablation technology enhanced by direct electrical current.
It offers the potential for incisionless, fertility-preserving, same-day procedures, with better outcomes and experience for patients and a more cost-effective option for health systems.
Ablatus is a spinout from the Norfolk and Norwich University Hospitals NHS Foundation Trust in the UK. We are backed by experienced angels and VC investors.
Our Mission
To revolutionise uterine health with minimally invasive and inclusive care
Our Technology
Luna is built on our patented technology, specifically designed for:
Larger and more
effective ablations
effective ablations
Incisionless access to the uterus
with a steerable probe
with a steerable probe
Better patient experience
and outcomes
and outcomes
Compatibility with existing ultrasound
systems
systems
Cost-effective treatment for greater access
Why Luna?
Better
- Fertility-preserving
- Incisionless
- More effective ablation of larger fibroids
- Improved access to hard-to reach fibroids
- Less discomfort using thinner & flexible probe
- Simpler design and application, less risks of device-related adverse effects
Faster
- Shorter procedural time
- Quicker access to treatment via outpatient than inpatient procedures
- Back to work within days instead of weeks as with open surgery
Cost-effective
- Lower device and operating costs
- Delivered in outpatient instead of inpatient setting
- Fewer consumables
- Compatible with common, existing ultrasound systems
- Lower staff training requirements
Faster
Shorter procedural time
Quicker access to treatment via
outpatient than inpatient
procedures
Back to work within days instead of
weeks as with open surgery
Better
Fertility-preserving Incisionless
More effective ablation of larger
fibroids. Improved access to hard-
to reach fibroids. Less discomfort
using thinner & flexible probe
Simpler design and application.
Cost-Effective
Lower device and operating costs
Delivered in outpatient instead of inpatient setting
Fewer consumables
Compatible with common, existing ultrasound systems
Lower staff training requirements
Partners
Investors
Our Team
Dr. Chung Looi
CEO
10 years in biomedical research & medtech Partnerships & BD US, EMEA, & Asia Insurer market Series A for US market access
Dr. Anne Blackwood
Chair, Director
20 years of medtech knowledge transfer & IP CEO of Health Tech Enterprise Former Chair & Co-Founder of Medovate
Dr. Natalie Hayes
Director
20 years of NHS clinical, medtech, & regulatory experience Director of multiple start-ups Qualified in medicine & law
Prof. Marcus Flather
Director
Professor of Medicine & Clinical Trials at University of East Anglia Director of Research at Norfolk & Norwich University Hospitals NHS Foundation Trust
Dr. Robert Smith
Senior Scientist
10 years of research in biological sciences 5 years of R&D at Ablatus Leads technology assessment
